The MMRF provides CME-accredited educational programs for healthcare professionals to learn more about multiple myeloma as well as current and emerging treatment options, including clinical trials from key leaders in myeloma. Access up-to-date information.
Treating Multiple Myeloma in 2017: New Agents, New Challenges
a webinar on the current state of practice for patients with multiple myeloma, held on Tuesday, December 13, 2016.
Conducted by Dr. Thomas G. Martin, III, from the University of California, San Francisco Medical Center and Dr. Suzanne Lentzsch from Columbia University Medical Center, this webinar reviews the clinical data underlying the FDA’s approval of the latest myeloma drugs and discusses where and how these newly approved agents fit in the current myeloma treatment schema.
Multiple Myeloma Patient Management: New Agents, New Challenges
Satellite Symposium preceding the 58th American Society of Hematology (ASH) Annual Meeting & Exposition
The multiple myeloma (MM) therapeutic landscape has significantly expanded, with 10 new drug approvals in the last 12 years. To help hematologist-oncologists keep pace with the rapid advancements in treatments, this satellite symposium provides updated information on the optimal strategies for managing patients with MM.
The Evolving State of Relapsed/Refractory Multiple Myeloma Treatment
A CNE satellite symposium held during the Oncology Nursing Society’s 41st Annual Congress
In 2015 four new agents were approved for the treatment of multiple myeloma (MM) in the
salvage setting, equipping oncology health professionals with more therapeutic options than ever before. But for oncology nurses, this progress also brings the challenge of managing new treatment-related toxicities. The content from this symposium provides current information to help oncology nurses maximize treatment outcomes for patients with relapsed/refractory MM.
Click here to participate in the interactive, enduring e-learning activity that provides updates on current practices in MM patient care, using a patient case study that invites learners to participate in the decision-making processes that will maximize treatment outcomes for patients with relapsed/refractory MM.
Building on Myeloma Therapy: Emerging Molecular Targets
and Immunotherapeutic Approaches
Presentations available from the CME-Certified Satellite Symposium
Sponsored by the MMRF
Treating Multiple Myeloma in 2017: New Agents, New ChallengesnOur webinar on the current state of practice for patients with multiple myeloma, Treating Multiple Myeloma in 2017: New Agents, New Challenges, was held on Tuesday, December 13, 2016.
Conducted by Dr. Tom Martin and Dr. Suzanne Lentzsch, this well-received webinar examined the clinical data underlying the FDA’s approval of the latest myeloma drugs, reviewed the mechanisms of action or these agents, and discussed where and how these newly approved agents fit in the current myeloma treatment schema. We are happy to announce that an archived version of this webinar is online now and available for CME credit. Earn your credits now
56-Year-Old Woman Relapsing Following Induction Therapy and Autologous Stem Cell TransplantationIn this interactive e-learning activity for oncology nurses, participants review the latest updates in MM patient care and make clinical decisions to maximize treatment outcomes for a virtual patient with relapsed/refractory MM. Earn your credits now
Multiple Myeloma Virtual PracticeA CME-certified curriculum on myeloma patient care that includes two interactive modules reviewing new therapies and highlighting strategies for optimizing treatment outcomes:
- New Developments in Multiple Myeloma Treatment– • The Main Conference Room presentation reviews recent data on myeloma diagnosis and management and follows a patient case through the course of his disease.
– In the RME Hot Seat, myeloma experts discuss the use of elotuzumab vs daratumumab in patients with relapsed/refractory disease; determining which agent to use at disease progression in lenalidomide-sensitive patients; the potential use of PD-1 inhibitors in combination therapy; and several other subjects of relevance to clinicians who see myeloma patients. Earn your credits now